RecruitingPhase 2NCT07725939
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Sponsor: UCB Biopharma SRL
Rincon, GA · +6 more sites